
1997-06-03
Microscopic
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Pharmaceuticals and Chemical Intermediates
Country / Region:
China
Company Type:
Listed company
Registered Capital:
¥129,929,634.02
Company Capability: Process Technology Development
Suzhou Amerigen Pharmaceuticals Company Limited is a high-tech enterprise specializing in the research and development, manufacturing, and marketing of dermatological topical medications. Focusing on the treatment of chronic inflammatory skin diseases, the company’s core product pipeline covers indications including psoriasis, atopic dermatitis, and corticosteroid-dependent dermatitis. Its primary products include topical dermatological formulations such as ointments, gels, and solutions. The company has commercially launched “Aifuning® Halometasone Ointment” (National Medical Product Administration Approval No.: H2023XXXX), one of the first dermatological topical corticosteroid generic drugs approved in China under the new registration classification. Its investigational product, “Meijinshu® Tacrolimus–Pimecrolimus Dual-Target Nanogel,” has completed Phase III clinical trials; trial data demonstrated a statistically significant prolongation of recurrence-free period versus monotherapy (p<0.01), with related findings published in the Journal of the European Academy of Dermatology and Venereology (2025). The company operates modern manufacturing facilities compliant with Good Manufacturing Practice (GMP) requirements and holds a “Pharmaceutical Production License” (Category Code: Dh). Its quality management system is certified to ISO 9001:2015, and it has completed process validation and stability studies for multiple investigational products. As of mid-2025, the company holds seven authorized invention patents; its core technologies encompass novel transdermal absorption technologies, microemulsion-based drug delivery systems, and optimized anti-inflammatory and antipruritic compound formulations. A representative patent is “A Synergistic Sustained-Release Gel Containing Halometasone and Tacrolimus and Preparation Method Thereof” (Patent No.: ZL202010XXXXXX.X). Leveraging local CDMO partners in Suzhou, the company has established an integrated layout covering active pharmaceutical ingredients (APIs) and finished dosage forms. Its current market coverage is concentrated in Grade II and above hospitals and specialized dermatology chain institutions in the East China region; it has not yet initiated overseas regulatory registration or export activities. The company offers clinical need-driven R&D collaboration, GMP-compliant manufacturing support, and professional promotion services for dermatological products to healthcare institutions, academic platforms, CDMO partners, and regional distribution channels.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
112
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































